Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words LOS ANGELES, CA, March 05, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new […]
Immix Biopharma 12 Month Review Progress Update
LOS ANGELES, Feb. 21, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. “The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease. We successfully […]
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a […]
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees U.S. observed prevalence of relapsed/refractory […]
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 05, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common […]
Immix Biopharma Announces Proposed Public Offering of Common Stock
LOS ANGELES, Feb. 05, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are […]
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
LOS ANGELES, CA, Jan. 24, 2024 — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products: “We applaud FDA’s vigilance. Relapsed/refractory AL Amyloidosis remains an unmet medical need with […]
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care LOS ANGELES, Jan. 04, 2024 — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined […]
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies LOS ANGELES, Dec. 18, 2023 — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that […]
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023 Best responder duration of response was 23.7 months with response ongoing as of December 10, […]